Synthesis, further biological evaluation and pharmacodynamics of newly discovered inhibitors of TNF-α production

Bioorganic and Medicinal Chemistry

Volumn 11, Issue 18, 2003, Pages 3937-3943

  Matsui, Toshiaki ^a   Kondo, Takashi ^a   Nakatani, Shingo ^a   Omawari, Nagashige ^a   Sakai, Masaru ^a   Mori, Hideaki ^a   Ogata, Akihito ^a   Kato, Junya ^a   Ohno, Hiroyuki ^a   Obata, Takaaki ^a   Nakai, Hisao ^a   Toda, Masaaki ^a  

^a ONO PHARMACEUTICAL CO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; PROTEIN INHIBITOR; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BIOSAFETY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG METABOLISM; DRUG POTENCY; DRUG SAFETY; DRUG SCREENING; DRUG SYNTHESIS; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; HUMAN TISSUE; IN VITRO STUDY; INJECTION; LIVER METABOLISM; MALE; NONHUMAN; NORMAL HUMAN; PHARMACODYNAMICS; RAT; SINGLE DRUG DOSE;

STAPHYLOCOCCUS PHAGE 3A;

EID: 0042591258     PISSN: 09680896     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0968-0896(03)00409-7     Document Type: Article

References (18)

1. (a) Camussi G., Lupia E. Drugs. 55:1998;613
2. (b) Arrieta O., Rodriguez-Reyna T.S., Sotelo J. Exp. Opin. Ther. Pat. 10:2000;601
3. (c) Tracey K.J., Cerami A. Annu. Rev. Med. 45:1994;491
4. (d) Marriott J.B., Westry M., Dalgleish A.G. Drug Disc. Today. 2:1997;273.
5. (a) Matsui T., Kondo T., Nishita Y., Itadani S., Nakatani S., Omawari N., Sakai M., Nakazawa S., Ogata A., Ohno H., Obata T., Nakai H., Toda M. Bioorg. Med. Chem. Lett. 12:2002;903
6. (b) Matsui T., Kondo T., Nishita Y., Itadani S., Tsuruta H., Fujita S., Omawari N., Sakai M., Nakazawa S., Ogata A., Mori H., Ohno H., Obata T., Nakai H., Toda M. Bioorg. Med. Chem. Lett. 12:2002;907
7. (c) Matsui T., Kondo T., Nishita Y., Itadani S., Nakatani S., Omawari N., Sakai M., Nakazawa S., Ogata A., Mori H., Terai K., Kamoshima W., Ohno H., Obata T., Nakai H., Toda M. Bioorg. Med. Chem. 10:2002;3757
8. (d) Matsui T., Kondo T., Nishita Y., Itadani S., Tsuruta H., Fujita S., Omawari N., Sakai M., Nakazawa S., Ogata A., Mori H., Kamoshima W., Terai K., Ohno H., Obata T., Nakai H., Toda M. Bioorg. Med. Chem. 10:2002;3787
9. (e) Matsui T., Takahashi S., Matsunaga N., Nakamura K., Omawari N., Sakai M., Kamoshima W., Terai K., Ohno H., Obata T., Nakai H., Toda M. Bioorg. Med. Chem. 10:2002;3807.
10. Petasis N.A., Zavialov I.A. J. Am. Chem. Soc. 120:1998;11798.
11. 1H NMR. Another by-product 17 was a diastereoisomer of 16. Diastereomeric excess (de) was determined by HPLC analysis (86% de, 16:18=93:7). Purification method has not been optimized yet.
12. (a) (5S)-2,2,5-Trimethyl-1,3-dioxolan-4-ol 14 was prepared by the modification of the known methods: Davis F.A., Sheppard A.C., Chen B-C., Haque M.S. J. Am. Chem. Soc. 112:1990;6679
13. (b) Kusumoto, T.; Hiyama, T.; Matsuitani, H.; Ichikawa, S., Japan Patent, JP8225477
14. 4 in acetone at room temperature for 3 days (32% yield).
15. Mikuls T.R., Moreland L.W. Exp. Opin. Pharmacother. 2:2001;75.
16. Drug Ther. Bull. (special issue) 2001, 39, 49.
17. Blam M.E., Stein R.B., Lichtenstein G.R. Am. J. Gastroenteral, 96:2001;1977.
18. Assche V.G., Rutgeerts P. Exp. Opin. Invest. Drugs. 9:2000;103.